98%
921
2 minutes
20
Background And Purpose: Enhanced lesion detection in prostate cancer is observed with late [ Ga]Ga-PSMA-11 PET/CT imaging compared to standard [ Ga]Ga-PSMA-11 PET/CT imaging (50-100 min p.i.). However, the poor image quality of late imaging using short axial field of view (SAFOV) PET/CT has hindered its sole clinical adoption. Conversely, the image quality of late imaging with a long axial field of view (LAFOV) [ Ga]Ga-PSMA-11 PET/CT fulfills clinical diagnostic requirements. Nonetheless, the diagnostic efficacy of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis and its impact on treatment decisions, compared to standard LAFOV [ Ga]Ga-PSMA-11 PET/CT, remains unclear. This study aims to compare the rate of PET positivity between late and standard LAFOV [ Ga]Ga-PSMA-11 PET/CT and to evaluate the influence of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis on treatment decisions relative to standard scans.
Methods: From January 2021 to April 2024, 127 patients with biochemical recurrence of prostate cancer post-radical prostatectomy were enrolled to undergo both standard and late LAFOV [ Ga]Ga-PSMA-11 PET/CT scans at Shanghai Renji Hospital. We compared the rate of PET positivity between the two modalities at the patient level and across different anatomical regions. We assessed the added diagnostic value of late LAFOV [ Ga]Ga-PSMA-11 PET/CT and its impact on modifying patient treatment plans.
Results: The image quality of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis in all patients met clinical diagnostic requirements. The rate of PET positivity of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis were significantly higher than those of standard LAFOV [ Ga]Ga-PSMA-11 PET/CT (80.31% [102/127] vs. 65.35% [83/127]; P < 0.001). Late LAFOV [ Ga]Ga-PSMA-11 PET/CT demonstrated higher lesion SUVmax (16.69 ± 16.42 vs. 11.91 ± 10.72, P < 0.001) and TBR (6.26 ± 7.21 vs. 3.44 ± 3.57, P < 0.001) compared to standard LAFOV scans. Additionally, 14.17% (18/127) of patients experienced changes in their treatment regimen due to the superior detection capabilities of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to the standard scan.
Conclusions: The rate of PET positivity of late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to standard LAFOV [ Ga]Ga-PSMA-11 PET/CT highlight its potential as a valuable diagnostic tool for biochemically recurrent prostate cancer. This study paves the way for using late LAFOV [ Ga]Ga-PSMA-11 PET/CT with forced diuresis for prostate cancer imaging in daily clinical practice, facilitating more accurate and timely diagnoses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00259-024-06980-8 | DOI Listing |
Lancet Oncol
September 2025
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Background: Quantitative parameters derived from gallium-68 [Ga]Ga-prostate-specific membrane antigen (PSMA)-11 PET-CT (PSMA-PET-CT) such as whole-body standardised uptake value (SUV)mean and total tumour volume (PSMA-TTV) have shown prognostic value for response to lutetium-177 [Lu]Lu-PSMA-617 monotherapy in patients with prostate cancer. Adding [Lu]Lu-PSMA-617 to enzalutamide improved overall survival compared with enzalutamide in patients with metastatic castration-resistant prostate cancer in the ENZA-p trial. This prespecified substudy of ENZA-p evaluated baseline PSMA-PET quantitative parameters as predictive and prognostic biomarkers for enzalutamide plus [Lu]Lu-PSMA-617 and enzalutamide monotherapy.
View Article and Find Full Text PDFQ J Nucl Med Mol Imaging
June 2025
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China -
Prostate cancer (PCa) is a heterogeneous disease and prevalent malignancy in men, necessitating accurate imaging techniques to facilitate effective diagnosis and management. Recent evidence has demonstrated that [F]fluorodeoxyglucose ([F]FDG) and prostate-specific membrane antigen (PSMA)-targeted PET tracers positron emission tomography/computed tomography (PET/CT) imaging can provide complementary biological information, thereby improving diagnostic accuracy and the assessment of lesion heterogeneity in patients with PCa. However, optimal protocols for PSMA/FDG dual-tracer PET/CT and PET/magnetic resonance (PET/MR) imaging remain under investigation.
View Article and Find Full Text PDFMol Imaging Biol
August 2025
Department of Nuclear Medicine & Endocrinology, PET/CT Center LINZ, Ordensklinikum, Linz, Austria.
Purpose: There are few prospective studies addressed toward the role of Gallium-labelled prostate-specific membrane antigen-11 ([Ga]Ga-PSMA-11) compared to [F]Fluorocholine ([F]FCH) PET/CT in clinical decision-making as prostate-specific PET-tracers. This study aims to evaluate the impact of PET/CT using [Ga]Ga-PSMA-11 and [F]FCH in clinical management of recurrent prostate cancer (PCa) and correlates imaging findings with clinical characteristics of PCa.
Procedures: Forty-six patients with PCa (mean age 68.
Theranostics
April 2025
Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
To assess the effectiveness of [Ga]Ga-PSFA-01 PET/CT in detecting primary tumors and metastatic lesions in patients with prostate cancer (PCa), and to compare the results with those from [Ga]Ga-PSMA-11 PET/CT and [Ga]Ga-FAPI-04 scans. Patients with histologically proven PCa were prospectively recruited and underwent [Ga]Ga-PSFA-01 PET/CT, of which: 25 participants also underwent [Ga]Ga-PSMA-11 PET/CT scan, 5 patients also underwent [Ga]Ga-FAPI-04 PET/CT scan, 3 patients underwent three modalities imaging. To assess the expression of PSMA and FAP, we obtained a pathological tissue section from a patient and performed immunohistochemical staining analysis.
View Article and Find Full Text PDFJ Nucl Med
May 2025
Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
The current prevalence of low intraprostatic uptake for staging prostate-specific membrane antigen (PSMA) PET ranges between 4.4% and 17% in retrospective studies. We aimed to define the prevalence and describe the outcomes of patients with low intraprostatic uptake on PSMA PET/CT in the prospective proPSMA study.
View Article and Find Full Text PDF